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Abstract
Background: Febrile malaria is the most common clinical manifestation of P. falciparum infection, and is often the primary
endpoint in clinical trials and epidemiological studies. Subjective and objective fevers are both used to define the endpoint,
but have not been carefully compared, and the relative incidence of clinical malaria by active and passive case detection is
unknown.
Methods: We analyzed data from cohorts under active and passive surveillance, including 19,462 presentations with fever
and 5,551 blood tests for asymptomatic parasitaemia. A logistic regression model was used to calculate Malaria Attributable
Fractions (MAFs) for various case definitions. Incidences of febrile malaria by active and passive surveillance were compared
in a subset of children matched for age and location.
Results: Active surveillance identified three times the incidence of clinical malaria as passive surveillance in a subset of
children matched for age and location. Objective fever (temperature$37.5uC) gave consistently higher MAFs than case
definitions based on subjective fever.
Conclusion: The endpoints from active and passive surveillance have high specificity, but the incidence of endpoints is
lower on passive surveillance. Subjective fever had low specificity and should not be used in primary endpoint. Passive
surveillance will reduce the power of clinical trials but may cost-effectively deliver acceptable sensitivity in studies of large
populations.
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Introduction
Childhood febrile disease is the most common clinical manifes-
tation of P. falciparum infection and is the endpoint most commonly
used to measure the public health burden of the disease, and to
assess the efficacy and effectiveness of preventative interventions
such as bed nets [1] or vaccines [2], including early phase trials [3].
Both active and passive surveillance methods have been proposed to
assess this endpoint and consensus guidelines on their use in vaccine
trials have been published [4]. However, there are no analyses that
examine the sensitivity and specificity of febrile malaria case
definitions identified by passive case detection, yet this is critical to
the accuracy of clinical trials and public health surveillance.
Defining clinical malaria in malaria endemic countries is
difficult because individuals may carry parasites without symp-
toms, and coincidental febrile episodes may have etiologies other
than malaria. The malaria-attributable fraction method uses
population data to estimate the frequency of true febrile malaria
among all febrile cases by fitting the risk of fever as a function of
parasite density using a logistic regression model[5]. This method
has been widely used under different malaria endemicities, and has
become a standard approach for deriving parasite density
thresholds to optimize sensitivity and specificity [6,7,8,9,10,11].
In active surveillance, individuals are visited regularly (monthly,
fortnightly or weekly) and assessed for malaria infection or disease
status. Provision is usually made to identify febrile episodes
between visits. This additional provision is often referred to as
‘‘passive surveillance’’, and hence the combination may be called
‘‘active and passive surveillance’’. However, the likelihood of
presentation between visits often rises as a result of the frequent
contact [12]. For this reason, and also to avoid confusion, we have
described the combination as active surveillance in this paper. The
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alternative, which we refer to as passive surveillance, relies only on
individuals’ attendance at health care facilities to identify episodes
of malaria.
It has been argued that active surveillance is more likely than
passive surveillance to misdiagnose asymptomatic parasitaemia
with a coincident, non-malaria cause of fever as a true malaria
case, leading to over-estimation of burden of malaria [13].
However, passive surveillance may miss clinical episodes that are
treated or resolve spontaneously without presentation to health
care facilities[14,15,16]. Cohorts under active surveillance often
record higher rates of malaria episodes than those under passive
surveillance [17,18] which may be interpreted either as the
inclusion of false-positives by the former, or an under-estimation of
the true malaria burden by the latter [19,20,21]. Estimates of the
global burden of malaria disease has relied on cohorts under active
case detection [22].
Comparison between surveillance methods can be confounded
by the location, malaria endemicity, age of individual being
followed and period of follow up. Therefore a formal comparison
of the relative incidence of endpoints detected by passive and
active surveillance requires matching by these variables, and has
not previously been undertaken.
Regardless of the surveillance method used, cases are often
defined by malaria parasitaemia in association with either an
objective fever (i.e. temperature.37.5) or a subjective fever. Use of
subjective fever in the case definition may lack specificity, and has
been avoided in some studies[6], but the specificity of this endpoint
has not been formally calculated.
We therefore analyzed data across four different cohorts in Kilifi
District, Kenya, in order to describe the sensitivity and specificity
of different case definitions from active and passive surveillance.
We also performed a formal comparison of specificity and
incidence of mild malaria endpoints from active and passive
surveillance in a sub-group of children who were matched by age,
period of follow up and location (implying similar malaria
endemicity).
Previous studies have suggested that a threshold of 2,500
parasites per ml adds specificity to the case definition [7], and so we
describe and compare estimates with and without this threshold.
Methods
Study cohorts and surveillance
We analyzed data from four cohorts which underwent different
surveillance methods for mild P. falciparum malaria, in order to
describe the sensitivity and specificity of case definitions within
cohorts and compare the specificity and incidences of the
endpoints from active and passive surveillance. The cohorts were
located in Chonyi, Ngerenya, Junju and Pingilikani sub-locations
of Kilifi District, on the coast of Kenya between January 1998 and
June 2009 (Figure1). The Junju cohort included children located
both in Junju and Pingilikani sub-locations. All cohorts were
nested within the wider demographic surveillance system (DSS)
which covers an area of about 891 km2 around Kilifi District
Hospital and involves six monthly re-enumeration visits to about
25,000 households. Junju and Pingilikani have generally been high
transmission areas, with moderate transmission in Chonyi, and
low transmission in Ngerenya, as evidenced by entomological
studies [23] and parasite rates [6,7]. However, transmission has
been falling throughout the period of study [24,25]. For the
purpose of this study we categorized the transmission intensity
based on concurrent parasite prevalence in each cohort.
Different follow up and blood slide evaluation protocols were
used in each cohort. In the Chonyi and Ngerenya cohorts, clinical
malaria episodes were detected using weekly active surveillance
implemented over the entire study period [7]. Children with
subjective or objective fever (axillary temperature$37.5uC) had
blood samples taken to estimate the parasite density from blood
smears. In contrast, in Junju blood smears were done only on
children with an objective fever (axillary temp$37.5uC) and
children with subjective fever without elevated temperature were
followed 6–12 hours later, and the temperature measurement
repeated. Blood smears were made if objective fever was confirmed
at this measurement. Clinicians reviewed all children who were
unwell but without objective fever. In addition while the parents of
the children in Chonyi and Ngerenya were instructed to report to
Kilifi District Hospital (20 km away) if the child had any symptoms
of disease at any time, in Junju, dispensaries were located within
5 km and trained field workers were available at all times in the
villages for passive surveillance. Pingilikani cohort was monitored
purely by passive surveillance at the Pingilikani dispensary, where
blood smears were done for all children presenting with a complaint
of fever (both objective and subjective fever). Sulfadoxine-
pyrimethamine was the first line anti-malarial drug used until early
2006 when the artemisinin base combination therapy (artemether-
lumefantrine) was introduced throughout Kenya.
Ethics statement
The details of consent procedures have been published
elsewhere [7,26]. Briefly, in Chonyi and Ngerenya, written
informed consent was obtained from parents/guardians of young
children and adults from randomly selected homesteads using an
approved consent form. In Junju written informed consent was
obtained from parents/guardians of children who earlier partic-
ipated in a non-efficacious malaria vaccine trial. Subsequently the
consent was sought for all the newborns from these homesteads.
Pingilikani dispensary cohort is part of a wider Demographic
Surveillance system with established recruitment process. The
clinical records of children in the cohort were obtained by
matching their personal identification numbers from anonymised
Demographic Surveillance System and dispensary database.
The approval for human participation in these cohorts was
given by the Kenya Medical Research Institute Scientific
Committee and National Review and the Ethical Committee of
the Kenya Medical Research Institute.
Laboratory investigations
Malaria parasitaemia was determined by examination of blood
smears stained with 2% Giemsa solution. For Junju, Pingilikani
dispensary, Chonyi and Ngerenya cohort, the number of asexual-
stage parasites/200 leukocytes was counted, and parasitaemia was
estimated on the basis of an assumed uniform white cell count;
8,000 leukocytes/mL. For members of the Junju cohort located in
the Pingilikani sub-location, parasitaemia was estimated on the
basis of actual leukocyte count measured for each blood smear.
Regression models for the determination of Malaria Attributable
Fraction used parasite densities calculated from a single method.
Only Plasmodium falciparum parasitaemia was included in the
analysis.
Calculation of Malaria Attributable Fraction
Malaria Attributable Fractions were used to estimate the
specificity of the malaria endpoints detected by different
surveillance methods. Cases were febrile children at the time of
surveillance visit. Control cases were afebrile healthy children seen
at the cross sectional bleeds during the follow up period. For
Pingilikani dispensary cohort, we used controls from Junju cross
sectional bleed. Junju is contiguous with and immediately to the
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south of Pingilikani. Malaria Attributable Fraction was determined
by using logistic regression to model the risk of fever as continuous
function of parasite density as developed by Smith et al [5].
Log
p
1{p
 
~azbxp
Where p is the probability that a subject with x parasite density
has fever and p is the power function of parasite density. The
power function maximizes likelihood estimation for the different
age groups, cohorts and surveillance methods and was used to
model the relationship between fever and parasite density as a
continuous function. The power function was re-optimized for
each fit of the model, hence the shape of the curve relating parasite
density to the probability of fever was allowed to vary for different
populations. Confidence intervals were calculated by the bootstrap
method using 1000 repeat samplings. Analysis was performed
using STATA software (version 9.0; STATA Corp). Only children
aged 0–5 years old were included in the analysis of general MAF.
Age specific MAF were estimated to investigate variation of MAF
with age for each cohort. Children who had objective fever and
also were reported to have subjective fever were included in the
sub-analysis of ‘‘objective fever’’ but not ‘‘subjective fever’’.
Incidence rate
Active surveillance in the Junju cohort located in Pingilikani
sub-location overlapped with passive surveillance at Pingilikani
dispensary. This overlap applied to the 105 children aged 5–17
months who were under active surveillance between May 2007
and April 2008. In order to define a comparable cohort under
passive surveillance at Pingilikani dispensary, we used the
demographic surveillance system to identify age- and location-
matched children during the same period. However, we did not
include children sharing a homestead with a child under active
surveillance in this matched cohort, to avoid a possible
contaminating effect of the homestead being visited. Incidence
rates of malaria clinical episodes were calculated by counting the
number of clinical episodes of malaria divided by the total time at
risk expressed as total person years at risk.
Results
The detailed characteristics of each cohort are shown in Table 1.
In total there were 7,606 children and 299,189 surveillance visits
across all four cohorts. Fever was documented in 19,462
surveillance visits and clinical malaria was diagnosed in 9,219
surveillance visits.
MAFs of clinical malaria with objective or subjective fever
Using a subjective history of fever in the case definition was
associated with a consistently lower MAF than objectively elevated
temperature (temp$37.5uC) independent of age. This difference
was more marked in the higher transmission cohorts (Chonyi and
Pingilikani) Table 2. As expected, using a threshold of .2500
parasite/ul increased the MAF for all case definitions. However,
among children with subjective fever in Chonyi the MAF was 59%
even after applying this threshold (Table 2).
In the Junju cohort, where blood smears were only made on
objectively febrile children, on only 8 out of 532 occasions (0.02%)
were children with a history of fever but no elevated temperature
found to have febrile malaria on a return visit conducted 6–
12 hours later. The children who had no objective fever at 6–
12 hours follow-up had a similar risk of a subsequent malaria
episode as the children (matched by season and age group) who
had no history of fever (HR: 0.9 95%CI 0.7–1.5, p value = 0.9).
Older children (2.5–5 years) had lower MAF than younger
children (0–2.5 years) which increased after using a parasite
threshold of .2500/mL (data not shown). However this difference
was less marked in a low transmission cohort (Ngerenya).
Parasite densities
Children under passive surveillance in Pingilikani had a
significantly higher geometric mean parasite density than children
under active surveillance in Junju [10,300/mL:95% CI: 9,800–
10,800 versus 4,775/mL:95%CI: 3,900–5,800]. Furthermore,
there was no variation in geometric mean parasite density with
distance from dispensary for the Pingilikani dispensary cohort
within 10 kilometers of the dispensary suggesting that distance to
healthcare was not a factor that determined the likelihood of
presentation (Figure 2).
Comparison of active and passive surveillance
Part of the Junju active cohort and the Pingilikani dispensary-
based cohort overlapped geographically (Figure 1). Among an age-,
time- and location-matched subgroups of these cohorts the Malaria
Attributable Fractions were similar (Table 3). However, the
incidence of clinical malaria identified by active surveillance was
over three times the incidence by passive surveillance. The mean
febrile temperature for passive surveillance at dispensary cohort was
38.6uC [95%CI: 38.6–38.7] compared with 38.3uC [95%CI: 38.2–
38.4] on active surveillance, although the geometric mean
parasitaemia were not statistically significantly different (Table 3).
Discussion
Clinical malaria is the endpoint most commonly used in the
field to measure the efficacy of interventions to prevent malaria,
and is often used to assess the public health burden. In a subset of
concurrent location- and age-matched cohorts, we found that
purely passive surveillance without specific prompts for visits
detected about one third of the episodes that would have been
identified by active surveillance yet MAFs were similar. Further-
more, cases with subjective fever but no objective evidence
(temperature ,37.5uC) had persistently lower Malaria Attribut-
able Fractions, even when a parasite density threshold was used.
It is surprising that the difference between rates for active and
passive case detection in matched subset of children was not larger.
Pingilikani dispensary serves a population of 4000 children under
5, and there had been no contact at the homestead or village level
to encourage attendance. In contrast, active surveillance required
one local fieldworker per 30–40 children monitored with frequent
contact at the homestead level (compared to 1 field worker per
.1,000 children in passive surveillance). The large numbers of
children using Pingilikani dispensary could be attributed to the
availability of adequate staff seven days a week, good malaria
diagnostic facilities and a constant antimalarial drug supply in
contrast to frequent supply problems reported elsewhere in Kenya
[27].
Nevertheless, fewer cases of malaria were identified at the
dispensary than would have been seen on active surveillance, and in
comparison children brought to the dispensary had significantly
higher mean temperatures when they were febrile but similar
symptomatic blood stage parasitaemia. This suggests that parents
were inclined to postpone presentation at the dispensary until more
acute overt illness. This was not simply the parents’ inability to
identify illness, since when field workers were made highly accessible
in the subset of Junju cohort children located in Pingilikani sub-
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Table 1. Baseline characteristics of cohorts used in the analysis.
Chonyi cohort Ngerenya cohort Pingilikani cohort Junju cohort
Number of children 315 575 6123 488
Follow up period analyzed 1998–2001 1998- June 2006 2003- June 2009 2006- March 2009
Median age in years (IQR)
at the start of follow up*
1.8 (3.3) 0.5(2.5) 1.6 (2.1) 2.5 (2.3)
Female % 153 (49%) 292 (51%) 2760 (45%) 202 (41%)
Transmission intensity High Low Moderate Moderate
Time at risk (years) 480.4 1930.4 25,144.1 864.8
Incidence rate 1.16[1.07–1.26] 0.63[0.6–0.67] 0.16[0.15–0.16] 0.93 [0.87–1.0]
Parasite prevalence# 30.8% 8.8% 18.7% 18.7%
Surveillance methods Weekly active surveillance
by field worker Passive
surveillance at district
hospital
Weekly active surveillance
by field worker Passive
surveillance at district
hospital
Passive visits at dispensary Weekly active surveillance
by field worker Passive
surveillance by field workers
and at dispensary
Indication for blood smear Axillary temperature $37.5
or history of fever in the
last 24 hours.
Axillary temperature $37.5
or history of fever in the
last 24 hours.
Axillary temperature $37.5
or history of fever in the
last 24 hours.
Axillary temperature $37.5
only
Number of total contact 29,353 178,292 28,384 59,604
#=Parasitaemia prevalence for all cohorts is summed up across the entire follow up period.
* =Only children less than 5 years old are included in the analysis
doi:10.1371/journal.pone.0015569.t001
Table 2. Malaria attributable fractions of malaria case definitions for any parasitaemia and .2500/uL parasites in the four cohorts.
Using objective
fever(temp$37.5 C)
Using subjective but
not objective fever
(temp,37.5 C) Using both case definitions
Chonyi cohort; active surveillance cohort
MAF for density .0/mL (95%CI) 68% (63%–71%) 44% (38%–50%) 56% (52%–61%)
Number of cases 558 1105 1663
MAF for density.2500/mL (95%CI) 81% (78%–84%) 59% (53%–64%) 70% (66%–74%)
Number of cases 456 671 1127
Ngerenya cohort; active surveillance cohort
MAF for density .0/mL (95%CI) 76% (73%–78%) 67% (65%–69%) 74% (72%–76%)
Number of cases 1225 1802 3028
MAF for density.2500/mL (95%CI) 83% (81%–85%) 81% (79%–83%) 83% (81%–85%)
Number of cases 1060 1253 2313
Pingilikani cohort; passive surveillance only cohort
MAF for density .0/mL (95%CI) 75% (74%–76%) 40% (39%–41%) 61% (60%–61%)
Number of cases 3954 3209 7163
MAF for density.2500/mL (95%CI) 85% (84%–86%) 54% (53%–55%) 73% (72%–74%)
Number of cases 2433 1609 4042
Junju cohort; active surveillance package cohort
MAF for density .0/mL (95%CI) 72% (69%–76%) NA NA
Number of cases 809 NA NA
MAF for density.2500/mL (95%CI) 85% (83%–88%) NA NA
Number of cases 636
doi:10.1371/journal.pone.0015569.t002
Figure 1. Location of the cohorts used in the study. The map shows the location of the cohorts used in the analysis. Colored regions represent
the locations where the cohorts were located. The sub-locations within each location are also shown, some of which have the same name as the
cohort.
doi:10.1371/journal.pone.0015569.g001
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location, the majority of malaria episodes were identified by
assessments initiated by the mothers between regular weekly visits.
There was no gradient of increasing parasite density with distance
from the dispensary, suggesting that the distance parents had to
travel with their children did not delay their treatment seeking. We
conclude that, in our setting, there is a barrier to approaching
medical staff in a health facility that does not exist with more
familiar, local field workers. Cases of febrile malaria not presenting
to the local dispensary may resolve without treatment or be treated
by anti-malarials bought by the parents from shops[28].
Passive surveillance in health care facilities has been reported to
be insensitive outside Africa [19,20] and globally [22]. As malaria
incidence falls, and it becomes increasingly important to identify the
majority of infections to sustain progress in control [29]. Novel
approaches, for instance passive surveillance operated by fieldwor-
kers stationed locally, deserve further consideration and evaluation.
The proportion of fevers attributable to malaria was persistently
lower in children with subjective fever than in children with
objective fever. Fever diagnosis by parents is unreliable [30,31].
Almost half of the cases with reported but not objective fever were
classified as not ‘‘true malaria’’ (i.e. they represented asymptomatic
parasitaemia in febrile patients with other etiologies). Based on our
results, the inclusion of reported fever cases in the endpoint of a
clinical trial, or in measuring the public health burden of malaria is
questionable.
Other factors may be relevant in defining the endpoint of a
study. Although the main outcome for most Phase IIb vaccine
trials in children would be clinical malaria, cluster randomized
Figure 2. Variation of geometric parasite density mean with distance from Pingilikani dispensary. Variation of geometric mean parasite
densities with distance from Pingilikani dispensary. Parasite densities have been converted into log10 scale.
doi:10.1371/journal.pone.0015569.g002
Table 3. Comparison between passive surveillance and active surveillance during follow up from May 2007 to May 2008 in a
subset of children aged 5–17months.
Passive surveillance# Active surveillance package*
Cohort location Pingilikani Junju-Pingilikani
Total number of children 561 105
Total number of contacts 932 3394
Total time at risk (person years) 562.6 91.6
Total malaria episodes h 58 34
Median contacts (Range) 1.6 (1–9) 32 (2–48)
Geometric mean parasite density (/mL) (95% CI) 14,700(8,700–24,900) 41,000(18,300–92,000)
Children with at least one malaria episode 33 14
Incidence of clinical malariah 0.10 [95%CI: 0.08–0.13] 0.37 [95% CI: 0.27–0.52]
Malaria Attributable Fraction .0/mL 92% (89%–95%) 88% (81%–96%)
Malaria Attributable Fraction .2500/mL 98% (95%–100%) 94% (87%–100%)
* = The active surveillance package consisted of passive surveillance at dispensary, passive surveillance at community by trained field worker with supervision from
study clinician and active weekly surveillance by trained field workers.
h=Clinical malaria defined as fever (axillary temperature$37.5uC plus parasitaemia of any density.
#=Passive surveillance package consisted of Passive surveillance at dispensary only. Numbers in brackets are 95% confidence interval unless indicated otherwise.
doi:10.1371/journal.pone.0015569.t003
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trials of transmission blocking vaccines might appropriately
include all parasitaemic cases identified regardless of the definition
of clinical malaria.
However, approximately half of all cases presenting had only
subjective fever, and so the loss in power of the study must be
balanced against the need to include endpoints of high specificity.
As an illustration, consider a hypothetical example where the
incidences of subjective and objective febrile malaria were both 10
per 100 children, and the respective MAFs were 54% and 85%
(using a threshold of 2,500 parasites/mL). A study would have 90%
power to detect 50% vaccine efficacy on including 1800 children
using objective fever alone as the endpoint, falling to 1300 children
using objective plus subjective fever. However, the estimate of
efficacy would be 43% using objective fever, but 35% using
objective fever plus subjective fever.
When we followed-up 532 children with subjective fever in Junju
cohort 6–12 hours later, we found only 4% (19/532) developed an
objective fever despite not receiving treatment and only 8 (0.02%)
had parasitaemia. Furthermore, children who remained afebrile at
6–12 hours of follow-up had a similar risk of subsequent malaria
episodes and other adverse events as other children matched by age
and time of follow up. This was done in a clinical trial where we
carefully monitored children and ensured 24 hour access to health
care, and would not be practical for routine healthcare or larger
studies, but demonstrates that subjective fever alone does not
identify children at a high risk of serious disease.
When estimating MAFs in the Pingilikani cohort, cross-sectional
surveys from neighboring Junju were used. Since malaria
transmission can vary significantly within short distances [32]
using controls from a different area could have biased our MAF
estimates. Furthermore controls were from a closely monitored
cohort which could underestimate the true population prevalence
of asymptomatic parasitaemia. However, these two directly
adjacent areas are similar in soil-type, housing and Entomological
Inoculation Rate (EIR) [23]. A potential estimation error is likely
to non-differentially affect both MAF estimates, and thus, is
expected not to bias incidence estimates.
Our results of the comparative analysis between passive
surveillance and active surveillance apply in the context of our
transmission patterns (seasonal/low to moderate) and age group
compared, and extrapolation to other transmission patterns and
age groups must be done with caution. Ngerenya and Chonyi
cohorts operated identical surveillance methods, but the difference
between objective fever and subjective fever was greater in Chonyi
(at moderate transmission intensity) than in Ngerenya (at low
transmission intensity). We have avoided comparisons between
surveillance in Junju and Ngerenya/Chonyi because both the
surveillance methodology and transmission intensity are different.
Another limitation of our study is its retrospective nature which is
prone to unmeasured confounding and bias.
In conclusion, the Malaria Attributable Fractions are similar
between active and passive surveillance, and passive surveillance at
the dispensary underestimates malaria occurrence substantially.
Cases of malaria identified on the basis of reported fever alone
should not be included in the primary endpoint of a clinical trial
since the specificity of the endpoint is low. Phase III studies
intended to lead to marketing licenses should test vaccines in the
standard setting of dispensary surveillance, but active surveillance
should be preferred in Phase IIb studies. Further studies are
needed to examine the potential factors inhibiting attendance at
health facilities. Improved malaria surveillance at local levels is
particularly important for supporting current malaria control
efforts and eventually, its elimination.
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